Nurix Therapeutics, Inc. (NRIX)
Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Who owns Nurix Therapeutics, Inc.
As filed with the SECHolders of 5% or more
9
Blackrock, Inc. holds 8.2% of Common Stock, as its SCHEDULE 13G/A filed Apr 23, 2025 says.
Directors and officers
12
report now, of 20 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 23, 2025 · Common Stock
Vestal Point Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 6.3% in May 15, 2026
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 6.17% in May 15, 2026
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share
Rubric Capital Management LP
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, $0.001 par value per share
Fmr LLC
SCHEDULE 13G · filed May 6, 2026 · COMMON STOCK · 4.1% in Nov 7, 2025
Perceptive Advisors LLC
SCHEDULE 13G · filed Sep 23, 2026 · Common Stock, par value $0.001 per share
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Redmile Group, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 9.9% in Apr 24, 2026
Commodore Capital LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.1% in Feb 14, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed May 12, 2025 · Common Stock · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
ARK Investment Management LLC
SCHEDULE 13G/A · filed Jan 10, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
What NRIX reports owning in othersstakes of 5% or more, and other ties
Nurix Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
48sales
0purchases
33sales on a scheduled plan
4people selling
$5.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer | 24 | $3.9M | 19 | 0 | $0 |
| Hansen Gwenn | Chief Scientific Officer | 12 | $800,000 | 8 | 0 | $0 |
| Van Houte Hans | Chief Financial Officer | 11 | $700,000 | 6 | 0 | $0 |
| Gregory Julia P | director | 1 | $500,000 | 0 | 0 | $0 |